Objective:To assess the concordance of tumour grade in specimens obtained from diagnostic cystoscopic biopsy and transurethral resection of bladder tumour(TURBT)and explore the risk factors of upgrading.Methods:The me...Objective:To assess the concordance of tumour grade in specimens obtained from diagnostic cystoscopic biopsy and transurethral resection of bladder tumour(TURBT)and explore the risk factors of upgrading.Methods:The medical records of 205 outpatients who underwent diagnostic cystoscopic biopsy before initial TURBT were retrospectively reviewed.Comparative analysis of the tumour grade of biopsy and operation specimens was performed.Tumour grade changing from low-grade to high-grade with or without variant histology was defined as upgrading.Logistic regression an-alyses were performed to identify the risk factors of upgrading.Results:For the 205 patients,the concordance of tumour grade between specimens obtained from biopsy and operation was 0.639.The concordance for patients who were preoperatively diagnosed with low-grade and high-grade was 0.504 and 0.912,respectively.Univariate and multivariate logistic regression analyses showed that older age,tumour multifocality,high neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),and low lymphocyte-to-monocyte ratio(LMR)were significantly associated with upgrading(odds ratio ranging from 0.412 to 4.364).The area under the curve of the different multivariate models was improved from 0.752 to 0.821,and decision curve analysis demonstrated a high net benefit when NLR,LMR,and PLR were added.Conclusion:Diagnostic cystoscopic biopsy may not accurately represent the true grade of primary bladder cancer,especially for outpatients with low-grade bladder cancer.Moreover,older age,tumour multifocality,high NLR,PLR,and low LMR are risk factors of upgrading,and systemic inflammatory markers improve the predictive ability.展开更多
Objective:To explore the value of Helicobacter pylori antibody (Hp-IgG) and serum pepsinogen (PG) combined with gastroscopy for screening early gastric cancer and precancerous lesions in high-risk groups, so as to pro...Objective:To explore the value of Helicobacter pylori antibody (Hp-IgG) and serum pepsinogen (PG) combined with gastroscopy for screening early gastric cancer and precancerous lesions in high-risk groups, so as to provide references for early clinical prevention and diagnosis.Methods: A retrospective analysis of our hospital from December 2014 to December 2017 were elderly patients with gastric cancer 304 cases, selected admitted 122 cases of elderly patients with gastric precancerous lesion (divided into superficial gastritis group, 70 cases of chronic atrophic gastritis group 52 cases) and 156 cases to the hospital in healthy volunteers as the control group. The status and the positive rate of Helicobacter pylori 13C urea breath test and compared two groups of patients with infection;using enzyme-linked immunosorbent assay of serum pepsinogen I (PG I), II (PG II) and pepsin Hp-IgG quantitative and qualitative diagnosis of individual and combined diagnostic efficiency and the comparison of three kinds of index.Results: The four groups were compared, the serum PG level of I from high to low were superficial gastritis group, normal control group, atrophic gastritis group and gastric cancer group, the differences were statistically significant;serum PG II levels from high to low in gastric cancer group and superficial gastritis group. Atrophic gastritis group, normal control group, the differences were statistically significant. Compared with the three groups, the positive rate of Hp-IgG was 90.7% in the gastric cancer group, 45.6% in the superficial gastritis group, 52.5% in the atrophic gastritis group, and the gastric cancer group was higher than that in the precancerous lesion group, but there was no difference between the precancerous lesions group. In terms of diagnostic efficacy, the specificity and sensitivity of Helicobacter pylori combined with pepsinogen were higher than those of the single diagnosis. Conclusion: Hp-IgG and PG combined with gastroscopy in screening high-risk gastric cancer and its precancerous lesions are of high specificity, high sensitivity and can be popularized in clinic.展开更多
Objective:This study aimed to explore the expression profile of transcription factor Runt-related transcription factor 2(RUNX2)in the synovial tissues of rheumatoid arthritis(RA)and its effect on the apoptosis of RA f...Objective:This study aimed to explore the expression profile of transcription factor Runt-related transcription factor 2(RUNX2)in the synovial tissues of rheumatoid arthritis(RA)and its effect on the apoptosis of RA fibroblast-like synovial cells(RA-FLS),and to screen new targets for the diagnosis,treatment and prognosis of RA.Methods:The expression and localization of mRNA and protein of RUNX2 in the synovial tissues were detected by real-time quantitative PCR(q PCR)and immunohistochemical staining,respectively.The effect of the expression of exogenous RUNX2 on the apoptosis process of RA-FLS cell line MH7A was investigated by flow cytometry,and the activation of NF-κB signaling pathway was detected by western blotting.Results:The expression of RUNX2 mRNA was significantly higher in the synovial tissues from RA patients,compared to that in the OA patients(P<0.05).RUNX2 protein was mainly localized in the nuclear of the RA synovial cells.Overexpression of exogenous RUNX2 could notably decrease the apoptosis of RA-FLS,which was substantially reversed by pretreatment with SN50,a specific inhibitor of NF-κB pathway.Compared with blank group and negative control group(p CMV6-AC-GFP-vector),the apoptotic rate of exogenous RUNX2 overexpressing(pCMV6-AC-GFP-RUNX2)MH7A cells was significantly decreased(P<0.05).NF-κB signaling pathway activity was significantly increased(P<0.05),and this effect could be effectively reversed by NF-κB signal pathway-specific inhibitor SN5.Conclusion:The high expression of UNX2 in RA synoviocytes could significantly inhibit the spontaneous apoptosis of cells,and it was related to the abnormal activation of NF-κB signaling pathway.In-depth studies of RUNX2/NF-κB signaling pathways will help to identify novel therapeutic targets for RA.展开更多
Objective:To study the value of serum tumor markers, carbohydrate antigen 125 (CA125), human epididymis secretory protein 4 (HE4) and ovarian cancer risk factor (ROMA) index in elderly patients with ovarian cancer, so...Objective:To study the value of serum tumor markers, carbohydrate antigen 125 (CA125), human epididymis secretory protein 4 (HE4) and ovarian cancer risk factor (ROMA) index in elderly patients with ovarian cancer, so as to provide a choice for clinical diagnosis.Methods:A total of 110 cases of ovarian cancer treated in our hospital in December 2017-December 2015 were selected as malignant group. In addition, 120 cases of benign ovarian tumors in the same period were selected as the benign group, and 92 healthy women who came to the hospital for health examination were selected as the control group. Serum HE4, CA125 levels and positive rates were detected by microparticle enzyme immunochemiluminescence assay, and ROMA index values were combined to assess the risk of ovarian cancer.Results:Malignant group serum CA125, HE4 level and ROMA index were significantly higher than those in the benign group and the control group, the level of CA125 in positive group was higher than control group, but the difference in level of HE4 and ROMA index between benign group and control group was not statistically significant. The positive rates of serum CA125, HE4 and ROMA index in malignant group were 76.4%, 92.7%, 96.4%, which were significantly higher than those in benign group (28.3%, 18.3%, 15%). The negative predictive value, positive predictive value, specificity and sensitivity of CA125 were all lower than those of HE4. The negative predictive value, positive predictive value, specificity and sensitivity of the combined ROMA index were higher than those of single diagnosis.Conclusions: Serum CA125, HE4 and ROMA index in elderly patients with ovarian cancer are significantly higher than those in elderly patients with benign ovarian tumors and healthy women. The combined diagnosis is the highest, with Gao Min's high sensitivity and specificity, which can be popularized in clinical practice.展开更多
Background and Aims:Ravidasvir(RDV)is a new generation pangenotypic hepatitis C virus(HCV)NS5A inhibitor,with high barrier to baseline resistance-associated species.This is the first phase 2/3 study conducted in China...Background and Aims:Ravidasvir(RDV)is a new generation pangenotypic hepatitis C virus(HCV)NS5A inhibitor,with high barrier to baseline resistance-associated species.This is the first phase 2/3 study conducted in China's Mainland confirming the efficacy and safety of RDV+ritonavir-boosted danoprevir+ribavirin for 12 weeks in treatment-naive noncirrhotic patients with genotype 1 infection in a large population.Methods:In this multicenter,randomized,doubleblinded,placebo-controlled phase 2/3 trial(NCT03362814),we enrolled 424 treatment-nafve,noncirrhotic adult HCV genotype 1 patients.All patients were randomized at 3∶1 ratio to receive a combination of RDV 200mg once daily plus ritonavir-boosted danoprevir 100mg/100mg twice daily and oral ribavirin 1000/1200mg/day(body weight<75/≥75 kg)(n=318)or placebo(n=106)for 12 weeks.The primary end-point was the rate of sustained virologic response 12 weeks after the end of treatment,and the safety was evaluated and compared between treatment and placebo groups.Results:The overall rate of sustained virological response at 12 weeks after treatment is 99%(306/309,95%,CI:97%-100%)under per protocol set analysis.All patients harboring baseline NS5A resistance-associated species in the treatment group(76/76,per protocol set)achieved sustained virological response at 12 weeks after treatment.No treatment-related serious adverse events were reported.Laboratory abnormalities showed mild or moderate severity(grade 1 and grade 2)in liver function tests.Conclusions:In treatment-na(i)ve,noncirrhotic HCV Chinese patients infected with HCV genotype 1,all-oral regimen of RDV+ritonavir-boosted danoprevir+ribavirin for 12 weeks was highly efficacious,safe,and well tolerated.展开更多
基金This study was supported by the Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University,China(No.XJTU1AF-CRF-2015-002 to DH).
文摘Objective:To assess the concordance of tumour grade in specimens obtained from diagnostic cystoscopic biopsy and transurethral resection of bladder tumour(TURBT)and explore the risk factors of upgrading.Methods:The medical records of 205 outpatients who underwent diagnostic cystoscopic biopsy before initial TURBT were retrospectively reviewed.Comparative analysis of the tumour grade of biopsy and operation specimens was performed.Tumour grade changing from low-grade to high-grade with or without variant histology was defined as upgrading.Logistic regression an-alyses were performed to identify the risk factors of upgrading.Results:For the 205 patients,the concordance of tumour grade between specimens obtained from biopsy and operation was 0.639.The concordance for patients who were preoperatively diagnosed with low-grade and high-grade was 0.504 and 0.912,respectively.Univariate and multivariate logistic regression analyses showed that older age,tumour multifocality,high neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),and low lymphocyte-to-monocyte ratio(LMR)were significantly associated with upgrading(odds ratio ranging from 0.412 to 4.364).The area under the curve of the different multivariate models was improved from 0.752 to 0.821,and decision curve analysis demonstrated a high net benefit when NLR,LMR,and PLR were added.Conclusion:Diagnostic cystoscopic biopsy may not accurately represent the true grade of primary bladder cancer,especially for outpatients with low-grade bladder cancer.Moreover,older age,tumour multifocality,high NLR,PLR,and low LMR are risk factors of upgrading,and systemic inflammatory markers improve the predictive ability.
基金National Natural Science Foundation of China No.30370747.
文摘Objective:To explore the value of Helicobacter pylori antibody (Hp-IgG) and serum pepsinogen (PG) combined with gastroscopy for screening early gastric cancer and precancerous lesions in high-risk groups, so as to provide references for early clinical prevention and diagnosis.Methods: A retrospective analysis of our hospital from December 2014 to December 2017 were elderly patients with gastric cancer 304 cases, selected admitted 122 cases of elderly patients with gastric precancerous lesion (divided into superficial gastritis group, 70 cases of chronic atrophic gastritis group 52 cases) and 156 cases to the hospital in healthy volunteers as the control group. The status and the positive rate of Helicobacter pylori 13C urea breath test and compared two groups of patients with infection;using enzyme-linked immunosorbent assay of serum pepsinogen I (PG I), II (PG II) and pepsin Hp-IgG quantitative and qualitative diagnosis of individual and combined diagnostic efficiency and the comparison of three kinds of index.Results: The four groups were compared, the serum PG level of I from high to low were superficial gastritis group, normal control group, atrophic gastritis group and gastric cancer group, the differences were statistically significant;serum PG II levels from high to low in gastric cancer group and superficial gastritis group. Atrophic gastritis group, normal control group, the differences were statistically significant. Compared with the three groups, the positive rate of Hp-IgG was 90.7% in the gastric cancer group, 45.6% in the superficial gastritis group, 52.5% in the atrophic gastritis group, and the gastric cancer group was higher than that in the precancerous lesion group, but there was no difference between the precancerous lesions group. In terms of diagnostic efficacy, the specificity and sensitivity of Helicobacter pylori combined with pepsinogen were higher than those of the single diagnosis. Conclusion: Hp-IgG and PG combined with gastroscopy in screening high-risk gastric cancer and its precancerous lesions are of high specificity, high sensitivity and can be popularized in clinic.
基金supported by Science and Technology Research Project in Shaanxi province(No.2014K11-03-06-10)
文摘Objective:This study aimed to explore the expression profile of transcription factor Runt-related transcription factor 2(RUNX2)in the synovial tissues of rheumatoid arthritis(RA)and its effect on the apoptosis of RA fibroblast-like synovial cells(RA-FLS),and to screen new targets for the diagnosis,treatment and prognosis of RA.Methods:The expression and localization of mRNA and protein of RUNX2 in the synovial tissues were detected by real-time quantitative PCR(q PCR)and immunohistochemical staining,respectively.The effect of the expression of exogenous RUNX2 on the apoptosis process of RA-FLS cell line MH7A was investigated by flow cytometry,and the activation of NF-κB signaling pathway was detected by western blotting.Results:The expression of RUNX2 mRNA was significantly higher in the synovial tissues from RA patients,compared to that in the OA patients(P<0.05).RUNX2 protein was mainly localized in the nuclear of the RA synovial cells.Overexpression of exogenous RUNX2 could notably decrease the apoptosis of RA-FLS,which was substantially reversed by pretreatment with SN50,a specific inhibitor of NF-κB pathway.Compared with blank group and negative control group(p CMV6-AC-GFP-vector),the apoptotic rate of exogenous RUNX2 overexpressing(pCMV6-AC-GFP-RUNX2)MH7A cells was significantly decreased(P<0.05).NF-κB signaling pathway activity was significantly increased(P<0.05),and this effect could be effectively reversed by NF-κB signal pathway-specific inhibitor SN5.Conclusion:The high expression of UNX2 in RA synoviocytes could significantly inhibit the spontaneous apoptosis of cells,and it was related to the abnormal activation of NF-κB signaling pathway.In-depth studies of RUNX2/NF-κB signaling pathways will help to identify novel therapeutic targets for RA.
文摘Objective:To study the value of serum tumor markers, carbohydrate antigen 125 (CA125), human epididymis secretory protein 4 (HE4) and ovarian cancer risk factor (ROMA) index in elderly patients with ovarian cancer, so as to provide a choice for clinical diagnosis.Methods:A total of 110 cases of ovarian cancer treated in our hospital in December 2017-December 2015 were selected as malignant group. In addition, 120 cases of benign ovarian tumors in the same period were selected as the benign group, and 92 healthy women who came to the hospital for health examination were selected as the control group. Serum HE4, CA125 levels and positive rates were detected by microparticle enzyme immunochemiluminescence assay, and ROMA index values were combined to assess the risk of ovarian cancer.Results:Malignant group serum CA125, HE4 level and ROMA index were significantly higher than those in the benign group and the control group, the level of CA125 in positive group was higher than control group, but the difference in level of HE4 and ROMA index between benign group and control group was not statistically significant. The positive rates of serum CA125, HE4 and ROMA index in malignant group were 76.4%, 92.7%, 96.4%, which were significantly higher than those in benign group (28.3%, 18.3%, 15%). The negative predictive value, positive predictive value, specificity and sensitivity of CA125 were all lower than those of HE4. The negative predictive value, positive predictive value, specificity and sensitivity of the combined ROMA index were higher than those of single diagnosis.Conclusions: Serum CA125, HE4 and ROMA index in elderly patients with ovarian cancer are significantly higher than those in elderly patients with benign ovarian tumors and healthy women. The combined diagnosis is the highest, with Gao Min's high sensitivity and specificity, which can be popularized in clinical practice.
基金Ascletis BioScience Co.,Ltd.provided financial support for this study
文摘Background and Aims:Ravidasvir(RDV)is a new generation pangenotypic hepatitis C virus(HCV)NS5A inhibitor,with high barrier to baseline resistance-associated species.This is the first phase 2/3 study conducted in China's Mainland confirming the efficacy and safety of RDV+ritonavir-boosted danoprevir+ribavirin for 12 weeks in treatment-naive noncirrhotic patients with genotype 1 infection in a large population.Methods:In this multicenter,randomized,doubleblinded,placebo-controlled phase 2/3 trial(NCT03362814),we enrolled 424 treatment-nafve,noncirrhotic adult HCV genotype 1 patients.All patients were randomized at 3∶1 ratio to receive a combination of RDV 200mg once daily plus ritonavir-boosted danoprevir 100mg/100mg twice daily and oral ribavirin 1000/1200mg/day(body weight<75/≥75 kg)(n=318)or placebo(n=106)for 12 weeks.The primary end-point was the rate of sustained virologic response 12 weeks after the end of treatment,and the safety was evaluated and compared between treatment and placebo groups.Results:The overall rate of sustained virological response at 12 weeks after treatment is 99%(306/309,95%,CI:97%-100%)under per protocol set analysis.All patients harboring baseline NS5A resistance-associated species in the treatment group(76/76,per protocol set)achieved sustained virological response at 12 weeks after treatment.No treatment-related serious adverse events were reported.Laboratory abnormalities showed mild or moderate severity(grade 1 and grade 2)in liver function tests.Conclusions:In treatment-na(i)ve,noncirrhotic HCV Chinese patients infected with HCV genotype 1,all-oral regimen of RDV+ritonavir-boosted danoprevir+ribavirin for 12 weeks was highly efficacious,safe,and well tolerated.
